miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting
Abstract Background 5-Azacytidine (AZA) combined with the BCL2 inhibitor Venetoclax (VEN) is the standard treatment for elderly acute myeloid leukemia (AML) patients or those who are unfit for intensive chemotherapy (elderly or unfit AML). However, an effective and rapid predictive biomarker to pred...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | Clinical Epigenetics |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13148-025-01823-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823862013411983360 |
|---|---|
| author | Yilan Xu Danyang Li Na Wang Bei Ge Chen Meng Min Zhao Zihan Lin Min Li Yigang Yuan Yue Cai Liuzhi Shi Shenmeng Gao Haige Ye |
| author_facet | Yilan Xu Danyang Li Na Wang Bei Ge Chen Meng Min Zhao Zihan Lin Min Li Yigang Yuan Yue Cai Liuzhi Shi Shenmeng Gao Haige Ye |
| author_sort | Yilan Xu |
| collection | DOAJ |
| description | Abstract Background 5-Azacytidine (AZA) combined with the BCL2 inhibitor Venetoclax (VEN) is the standard treatment for elderly acute myeloid leukemia (AML) patients or those who are unfit for intensive chemotherapy (elderly or unfit AML). However, an effective and rapid predictive biomarker to predict treatment outcome remains elusive. Methods miR-182 promoter methylation was measured in 94 AZA + VEN-treated elderly or unfit AML patients and 20 normal controls (NCs) samples. To determine whether miR-182 promoter methylation is a predictive marker of clinical outcomes in AZA + VEN-treated AML patients in a real-world setting, we analyzed and compared the complete remission (CR)/CR with incomplete hematologic recovery (CRi) rate, overall survival (OS), and leukemia free-survival (LFS) across different methylation groups: miR-182 promoter hypomethylation (median value < 20.21%) and hypermethylation (> 20.21%) in a retrospective study. Results The average methylation frequency was markedly higher in 94 AZA + VEN-treated elderly or unfit AML patients than that in 20 NCs. However, some AML patients (11.7%) still presented low miR-182 promoter methylation (< 10%). The average time to obtain CR/CRi was shorter in AML patients with miR-182 promoter hypermethylation than AML with hypomethylation. Moreover, the median OS and LFS were longer in AML patients with miR-182 promoter hypermethylation than AML with hypomethylation. Finally, the area under the curve (AUC) for 1-year mortality was 0.831, for 2-year was 0.788, and for 3-year was 0.800. Conclusions AML patients with miR-182 promoter hypermethylation have better outcomes. miR-182 promoter methylation is a predictive biomarker for AZA + VEN-treated AML patients. |
| format | Article |
| id | doaj-art-f05a84c4f4294814b68e700f96547ff0 |
| institution | Kabale University |
| issn | 1868-7083 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Clinical Epigenetics |
| spelling | doaj-art-f05a84c4f4294814b68e700f96547ff02025-02-09T12:42:51ZengBMCClinical Epigenetics1868-70832025-02-0117111310.1186/s13148-025-01823-1miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world settingYilan Xu0Danyang Li1Na Wang2Bei Ge3Chen Meng4Min Zhao5Zihan Lin6Min Li7Yigang Yuan8Yue Cai9Liuzhi Shi10Shenmeng Gao11Haige Ye12Department of Hematology, The First Affiliated Hospital of Wenzhou Medical UniversityMedical Research Center, The First Affiliated Hospital of Wenzhou Medical UniversityHealth Care Center, The First Affiliated Hospital of Wenzhou Medical UniversityInfection Control Department, Eye Hospital, Wenzhou Medical UniversityMedical Research Center, The First Affiliated Hospital of Wenzhou Medical UniversityMedical Research Center, The First Affiliated Hospital of Wenzhou Medical UniversityMedical Research Center, The First Affiliated Hospital of Wenzhou Medical UniversityMedical Research Center, The First Affiliated Hospital of Wenzhou Medical UniversityMedical Research Center, The First Affiliated Hospital of Wenzhou Medical UniversityDepartment of Clinical Medicine, Wenzhou Medical UniversityMedical Research Center, The First Affiliated Hospital of Wenzhou Medical UniversityMedical Research Center, The First Affiliated Hospital of Wenzhou Medical UniversityDepartment of Hematology, The First Affiliated Hospital of Wenzhou Medical UniversityAbstract Background 5-Azacytidine (AZA) combined with the BCL2 inhibitor Venetoclax (VEN) is the standard treatment for elderly acute myeloid leukemia (AML) patients or those who are unfit for intensive chemotherapy (elderly or unfit AML). However, an effective and rapid predictive biomarker to predict treatment outcome remains elusive. Methods miR-182 promoter methylation was measured in 94 AZA + VEN-treated elderly or unfit AML patients and 20 normal controls (NCs) samples. To determine whether miR-182 promoter methylation is a predictive marker of clinical outcomes in AZA + VEN-treated AML patients in a real-world setting, we analyzed and compared the complete remission (CR)/CR with incomplete hematologic recovery (CRi) rate, overall survival (OS), and leukemia free-survival (LFS) across different methylation groups: miR-182 promoter hypomethylation (median value < 20.21%) and hypermethylation (> 20.21%) in a retrospective study. Results The average methylation frequency was markedly higher in 94 AZA + VEN-treated elderly or unfit AML patients than that in 20 NCs. However, some AML patients (11.7%) still presented low miR-182 promoter methylation (< 10%). The average time to obtain CR/CRi was shorter in AML patients with miR-182 promoter hypermethylation than AML with hypomethylation. Moreover, the median OS and LFS were longer in AML patients with miR-182 promoter hypermethylation than AML with hypomethylation. Finally, the area under the curve (AUC) for 1-year mortality was 0.831, for 2-year was 0.788, and for 3-year was 0.800. Conclusions AML patients with miR-182 promoter hypermethylation have better outcomes. miR-182 promoter methylation is a predictive biomarker for AZA + VEN-treated AML patients.https://doi.org/10.1186/s13148-025-01823-15-AzacytidineVenetoclaxDNA methylationAcute myeloid leukemia |
| spellingShingle | Yilan Xu Danyang Li Na Wang Bei Ge Chen Meng Min Zhao Zihan Lin Min Li Yigang Yuan Yue Cai Liuzhi Shi Shenmeng Gao Haige Ye miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting Clinical Epigenetics 5-Azacytidine Venetoclax DNA methylation Acute myeloid leukemia |
| title | miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting |
| title_full | miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting |
| title_fullStr | miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting |
| title_full_unstemmed | miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting |
| title_short | miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting |
| title_sort | mir 182 promoter hypermethylation predicts the better outcome of aml patients treated with aza ven in a real world setting |
| topic | 5-Azacytidine Venetoclax DNA methylation Acute myeloid leukemia |
| url | https://doi.org/10.1186/s13148-025-01823-1 |
| work_keys_str_mv | AT yilanxu mir182promoterhypermethylationpredictsthebetteroutcomeofamlpatientstreatedwithazaveninarealworldsetting AT danyangli mir182promoterhypermethylationpredictsthebetteroutcomeofamlpatientstreatedwithazaveninarealworldsetting AT nawang mir182promoterhypermethylationpredictsthebetteroutcomeofamlpatientstreatedwithazaveninarealworldsetting AT beige mir182promoterhypermethylationpredictsthebetteroutcomeofamlpatientstreatedwithazaveninarealworldsetting AT chenmeng mir182promoterhypermethylationpredictsthebetteroutcomeofamlpatientstreatedwithazaveninarealworldsetting AT minzhao mir182promoterhypermethylationpredictsthebetteroutcomeofamlpatientstreatedwithazaveninarealworldsetting AT zihanlin mir182promoterhypermethylationpredictsthebetteroutcomeofamlpatientstreatedwithazaveninarealworldsetting AT minli mir182promoterhypermethylationpredictsthebetteroutcomeofamlpatientstreatedwithazaveninarealworldsetting AT yigangyuan mir182promoterhypermethylationpredictsthebetteroutcomeofamlpatientstreatedwithazaveninarealworldsetting AT yuecai mir182promoterhypermethylationpredictsthebetteroutcomeofamlpatientstreatedwithazaveninarealworldsetting AT liuzhishi mir182promoterhypermethylationpredictsthebetteroutcomeofamlpatientstreatedwithazaveninarealworldsetting AT shenmenggao mir182promoterhypermethylationpredictsthebetteroutcomeofamlpatientstreatedwithazaveninarealworldsetting AT haigeye mir182promoterhypermethylationpredictsthebetteroutcomeofamlpatientstreatedwithazaveninarealworldsetting |